Archive for 2011

The strength of pharmaceutical IPRs vis-à-vis foreign direct investment in clinical research: Preliminary findings

This article examines the effect of the intellectual property (IP) environment in developing countries on the level of foreign direct investment (FDI) and technology transfer occurring in the biopharmaceutical field in these countries. In particular, i…

Innovation in R&D: Using design thinking to develop new models of inventiveness, productivity and collaboration

By adapting insights and methodologies from design thinking, a modern scientific R&D organization may have the potential to increase the speed, inventiveness and vitality of their output and become an explosive engine of growth. Modern design consu…

Biotechnology commercialisation in universities of developing countries: A review of the University of Ibadan, Nigeria

The British colonial administration established the University of Ibadan (UI) in 1948 as an extension of the University College London and it became Nigeria’s first full-fledged and premier university in 1962. The university comprises 13 faculties and …

Journal of Commercial Biotechnology — November 2011 issue now available

The November 2011 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract for each paper: Journal of Commercial Biotechnology Vol 17, Issue 4 (2011) Exciting changes Yali Friedman Full details at the Journal of Commercial Biotechnology New technologies for neglected diseases: Can tax credits help […]

New technologies for neglected diseases: Can tax credits help biotechnology companies advance global health?

Biotechnology companies can play an important role in advancing technologies for global health. Initiatives such as Genzyme’s Humanitarian Assistance for Neglected Diseases and Alnylam’s Intellectual Property (IP) contributions to the Pool for Open Inn…

Where in the United States are drugs invented?

Following on the heels of my post on Globalization in the Pharmaceutical Industry, it is also useful to examine the distribution of inventorship across the United States. The stakes aren’t quite as high here — public health and national security don’t come in to play — but there still are important implications for economic development. […]

Pocket Biotechnology Industry Primer and Glossary

I’ve just published the Pocket Biotechnology Industry Primer and Glossary as an ebook. This book, which was previously only available as a printed book, is now available in digital format, which means greater convenience and a significant price reduction. This primer and glossary presents a broad, accessible, and comprehensive overview of the biotechnology industry and […]

Where in the world are drugs invented? Measuring pharmaceutical globalization.

The global locations of drug invention are important for public health, economic development, and national security reasons. Inventors tend to focus on diseases endemic to where they live. This is one of the problems of neglected diseases — there are few/no researchers working on certain diseases, which can lead to significant public health problems. Drugs […]

Moving a foreign biotechnology company to the United States is easy as stealing in church

“What is the biggest challenge in moving a foreign biotechnology company to the United States?” I asked this question at the Delaware-New Jersey-Pennsylvania annual biotechnology conference and received a surprising response. The consensus was neatly stated by one of the panelists: “Moving to the US is like stealing in church.” For all the problems one […]